Litfulo (ritlecitinib) and olumiant (baricitinib) are both oral medications that may be used to treat certain autoimmune conditions Olumiant is a janus kinase (jak) inhibitor, and litfulo inhibits jak3 and the tec kinase family. Litfulo is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older Not recommended for use in combination with other jak • for dosage interruption for certain adverse reactions, see full prescribing information Find patient medical information for litfulo (ritlecitinib) on webmd including its uses, side effects and safety, interactions, pictures, warnings, and user ratings Litfulo (ritlecitinib) capsules are formulated with ritlecitinib tosylate, a kinase inhibitor
Ritlecitinib tosylate is a white to off white to pale pink solid which is freely soluble in water. Litfulo® (ritlecitinib) full patient information medication page for patients to search for scientific information & prescribing information about pfizer medications in the us. Litfulo (ritlecitnib) is a selective dual janus kinase 3 (jak3) and tyrosine protein (tec) kinase inhibitor approved by the u.s Food and drug administration (fda) for adults and adolescents 12 years and older with severe alopecia areata (aa) (1) The fda approved litfulo for aa in june 2023.
OPEN
